Summary
A good tumoricidal activity of vindesine (VDS) has been reported in a variety of animal tumors and in human leukemias and lymphomas. We treated 22 patients who had received no prior chemotherapy and were suffering from a variety of malignant neoplasms with 0.5 mg/m2 to 3.0 mg/m2 VDS i. v. once or three times at weekly intervals and recorded the clinical, hematologic, and especially, neurological side effects.
Clinically we observed fatigue in nine patients, paresthesias in seven, myalgias in three, vertigo and diarrhea in two, and skin pains, tinnitus, gastric pains, alopecia, and tremor in one patient each. There was no obvious dose-action relationship. Paravenous injection caused cellulitis similar to that seen with vincristine. No side effects were apparent in liver (SGPT) and renal (creatinine) function tests. Hematologically there was a clear trend toward leukopenia with higher doses of DVA and a mean increase in the thrombocyte count by 51x103/mm3 was found (sign test: P<0.05). The hemoglobin level did not change.
Clinical neurological examination and monitoring by electroneurography revealed no changes in tensiometer performance, motor and sensory nerve conduction velocity, motor or sensory nerve action potential amplitudes, or H-reflex responses. There was dose-related diminution of the proprioceptive reflexes, especially in the lower extremities. Even with as little as 2.0 mg/m2 VDS i. v. at weekly intervals for 3 weeks Achilles and patellar tendon reflexes were diminished or absent in all patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adamson, R. H., Dixon, R. L., Ben, M., Crews, L., Shohet, S. B., Rall, D. P.: Some pharmacological properties of vincristine. Arch. Int. Pharmacodyn. 157, 299 (1965)
Ahn, Y. S., Harrington, W. J., Seelman, R. C., Eytel, C. S.: vincristine therapy of idiopathic and secondary thrombocytopenias. N. Engl. J. Med. 291, 376 (1974)
Ahn, Y. S., Byrnes, J. J., Harrington, W. J., Crayer, M. L., Smith, D. S., Brunskill, D. E., Lorraine, M. P.: The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets. N. Engl. J. Med. 298, 1101 (1978)
Anderson, P. J., Song, S. K., Slotwinter, P.: The fine structure of spheromembranous degeneration of skeletal muscle induced by vincristine. J. Neuropathol. Exp. Neurol. 26, 15 (1967)
Blum, R. H., Dawson, D. M.: Vindesine — Phase-I study of a vinca alkaloid. Proc. AACR/ASCO 17, 108 (1976)
Bodey, G. P., Freireich, E. J.: Initial clinical studies of vindesine (desacetyl vinblastine amide sulfate). Proc. AACR/ASCO 17, 128 (1976)
Bradley, W. G., Lassman, L. P., Pearce, G. W., Walton, J. N.: The neuromyopathy of vincristine in man. J. Neurol. Sci. 10, 107 (1970)
Burdman, J. A.: A note on the selective toxicity of vincristine on chick-embryo sensory ganglia in tissue culture. J. Natl. Cancer Inst. 37, 331 (1966)
Caccia, M. R., Comotti, B., Ubiali, E., Lucchetti, A.: Vincristine polyneuropathy in man. J. Neurol. 216, 21 (1977)
Carbone, P. E., Bono, V., Frei, E., III., Brindley, C. O.: Clinical studies with vincristine. Blood 21, 640 (1963)
Croft, P. B., Urich, H., Wilkinson, M.: Peripheral neuropathy of sensorimotor type associated with malignant disease. Brain 90, 31 (1967)
Dixon, W. J., Mood, A. M.: The statistical sign test. J. Am. Statist. Assoc. 41, 557 (1946)
Dyke, W. R., Nelson, R. L.: Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate). Cancer Treat. Rev. 4, 135 (1977)
Dyke, R. W., Nelson, R. L.: Phase I–II clinical investigation of vindesine (desacetyl vinblastine amide sulfate). Curr. Chemother. 2, (Abstract 640) (1978)
Freund, H. J., Kendel, K., Obrecht, P.: Zur Klinik und Pathophysiologie der Vincristinwirkungen am Nervensystem. Dtsch. Z. Nervenheilk. 196, 319 (1969)
Gottschalk, P. G., Dyck, P. J., Kiely, J. M.: Vinca alkaloid neuropathy: nerve biopsy studies in rats and man. Neurology 18, 875 (1968)
Krivit, W., Hammond, D.: Phase-II study of vindesine in childhood advanced malignancies. Curr. Chemother. 2, (Abstract 642) (1978)
Loeb, E., Hill, J. M., Pardue, A., Khan, A., Hill, N. O., King, J. J., Hill, R.: Vindesine, a new vinca alkaloid in the treatment of leukemias and lymphomas. Curr. Chemother. 2, (Abstract 643) (1978)
McLeod, J. G., Penny, R.: Vincristine neuropathy: an electrophysiological and histological study. J. Neurol. Neurosurg. Psychiatry 32, 297 (1969)
Salmon, S. E., Hamburger, A.: Immunoproliferation and cancer: A common macrophage-derived promoter substance. Lancet 1978 1, 1289
Sandler, S. G., Tobin, W., Henderson, E. S.: Vincristine-induced neuropathy. Neurology 19, 367 (1969)
Schochet, S. S., Lampert, P. W., Earle, K. M.: Neuronal changes induced by intrathecal vincristine sulfate. J. Neuropathol. Exp. Neurol. 27, 645 (1968)
Tan, C.: Clinical and pharmacokinetic studies of vindesine in 35 children with malignant diseases. Curr. Chemother. 2, 1326 (1978)
Tobin, W. E., Sandler, G.: Depression of muscle spindle function with vincristine. Nature 212, 90 (1966)
Uy, L. Q., Moen, T. H., Johns, R. H., Owens, A. H., Jr.: Vincristine neurotoxicity in rodents. Johns Hopkins Med. J. 121, 349 (1967)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Obrist, R., Paravicini, U., Hartmann, D. et al. Vindesine a clinical trial with special reference to neurological side effects. Cancer Chemother. Pharmacol. 2, 233–237 (1979). https://doi.org/10.1007/BF00257186
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257186